CN103952466B - 多核苷酸引物 - Google Patents
多核苷酸引物 Download PDFInfo
- Publication number
- CN103952466B CN103952466B CN201310752245.5A CN201310752245A CN103952466B CN 103952466 B CN103952466 B CN 103952466B CN 201310752245 A CN201310752245 A CN 201310752245A CN 103952466 B CN103952466 B CN 103952466B
- Authority
- CN
- China
- Prior art keywords
- primer
- sequence
- seqidno
- nucleotide
- sudden change
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 39
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 39
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 39
- 239000002773 nucleotide Substances 0.000 claims abstract description 49
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 49
- 230000000295 complement effect Effects 0.000 claims abstract description 19
- 230000008859 change Effects 0.000 claims description 44
- 238000012360 testing method Methods 0.000 claims description 35
- 238000001514 detection method Methods 0.000 claims description 18
- 101150063858 Pik3ca gene Proteins 0.000 claims description 17
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 16
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 7
- 239000000523 sample Substances 0.000 description 33
- 241000239226 Scorpiones Species 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 20
- 108091093088 Amplicon Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 102200085789 rs121913279 Human genes 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 238000010791 quenching Methods 0.000 description 11
- 230000000171 quenching effect Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 102200085788 rs121913279 Human genes 0.000 description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 229940048102 triphosphoric acid Drugs 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- -1 feces Substances 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
含有以下引物序列之一或其互补序列的至少最后6个核苷酸的多核苷酸：SEQ.ID NO：3-16,18,20-33,35或37-39。
Description
本申请是国际申请PCT/GB2008/003306，国际申请日2008年9月29日，中国国家阶段申请号200880110038.7的发明专利申请的分案申请。
技术领域
本发明涉及多核苷酸、含有多核苷酸的试剂盒，以及在基因中检测突变存在与否的方法。
背景技术
磷酯酰肌醇3-激酶(PI3K)是参与细胞信号传递的一大类脂质激酶。PI3K-AKT途径在许多类肿瘤中被激活，导致细胞生长、增殖和存活异常(补充的1篇近期综述)。近来，在人癌症中鉴定出了1A型PI3K(PI3KCA)催化亚基中的突变[1]。这些突变在致癌作用中的确切作用仍然并没有被明确确定，但随着许多靶向PI3K抑制剂的开发，突变检测对于患者筛选来说变得日益重要。这些突变的检测中的技术难题来自于可能只包含少量突变序列的肿瘤活组织切片的限制。另外，从石蜡包埋组织提取的DNA常常已被降解且质量很差。测序检测所需要的突变DNA的最低水平是15-25%，因此对于开发能在异源样品中检测少量突变的等位基因的灵敏的检测法以及进行所述检测法所需的产品具有迫切的需求。
本发明试图满足该需求。
发明内容
本发明提供了对肿瘤引起的PIK3CA突变的灵敏耐用的检测法。
根据本发明的一个方面，提供了一种多核苷酸，其含有下列引物序列之一的至少最后6个核苷酸：SEQ.IDNO.3-16,18,20-33,35或37-39，或其互补序列。也就是说，所述多核苷酸含有下列引物序列之一3’末端的至少6个核苷酸：SEQ.IDNO.3-16,18,20-33,35或37-39，或其互补序列。
优选地，所述多核苷酸包含下列引物序列之一、或其互补序列、或与其具有80%、90%、95%或99%序列一致性的序列3’末端8、10、12、14、17、18或20个核苷酸或整个序列的至少75%的核苷酸：SEQIDNO.3-16、18、20-33、35或37-39。
在本发明的一些实施方式中，提供了一种多核苷酸，其包含以下引物序列之一3’末端10个核苷酸的至少75%的核苷酸：SEQ.IDNO.3-16、18、20-33、35或37-39，或其互补序列。
通常，所述多核苷酸短于100个核苷酸，优选短于80个核苷酸，更优选短于60个核苷酸，更优选短于40个核苷酸，更优选短于30个核苷酸。
优选地，所述多核苷酸还含有淬灭基团和荧光团。
通常，所述淬灭基团和荧光团由含有第一和第二区域的核苷酸尾序列隔开，其中所述第一区域的核苷酸与第二区域的核苷酸互补但呈反向，从而所述第一区域与第二区域的杂交导致所述淬灭基团与所述荧光团足够靠近，以淬灭所述荧光团。
优选地，所述尾序列还含有第三区域，其具有与PIK3CA基因的一个区域互补的序列。
优选地，所述多核苷酸含有SEQIDNO:18的3’末端的至少6个核苷酸，并且所述尾序列含有SEQ.IDNO.17。
或者，所述多核苷酸含有SEQIDNO:35的3’末端至少最后的核苷酸，并且所述尾序列含有SEQ.IDNO.34。
或者，所述多核苷酸含有SEQIDNO:39的3’末端至少最后的核苷酸，并且所述尾序列含有SEQ.IDNO.38。
通常，所述淬灭基团含有Dabcyl。
优选地，所述荧光团含有Hex,Fam或Rox。
根据本发明的另一个方面，提供了一种含有本发明的至少两种多核苷酸的试剂盒。
优选地，所述试剂盒含有包含SEQIDNO.18的多核苷酸和包含SEQIDNO.3-16之一的多核苷酸;或含有包含SEQIDNO.35的多核苷酸和包含SEQIDNO.20-33之一的多核苷酸;或含有包含SEQIDNO.39的多核苷酸和包含SEQIDNO.37的多核苷酸。
通常，所述试剂盒还含有核苷三磷酸，聚合酶和/或缓冲液。
根据本发明的另一个方面，提供了将本发明所述的多核苷酸或试剂盒，或含有SEQ.IDNO.3-16,18,20-33或35或其互补序列3’末端6个核苷酸中的4或5个的多核苷酸用于检测含有PIK3CA基因的至少一个片段的核酸样品中的突变的用途。
优选地，所述核酸样品中的PIK3CA基因所述片段长至少10个核苷酸，优选长20个核苷酸，更优选长30个核苷酸，和更优选长40个核苷酸。
根据本发明的另一个方面，提供了一种检测PIK3CA基因中突变存在与否的方法，该方法包括以下步骤：
a)混合含有PIK3CA基因的至少一个片段的核酸样品和一条多核苷酸，其含有下列引物序列之一或其互补序列3’末端至少6个核苷酸：SEQIDNO.3-16或20-33；和
b)检测所述多核苷酸与所述核酸样品的杂交，其中杂交表示突变的存在。
通常，所述多核苷酸含有下列引物序列之一：SEQIDNO：3-16或20-33。
优选地，该方法还在步骤a)前包括以下步骤：用热循环核酸扩增，优选PCR扩增PIK3CA基因所述片段的拷贝数。
优选地，步骤b)包括用所述多核苷酸作为第一引物进行DNA聚合，并检测聚合的延伸产物。
通常，步骤b)包括以下步骤：将所述核酸样品和多核苷酸与对应于所述多核苷酸互补区域下游的PIK3CA序列所述片段的一个区域的第二引物混合，并对该混合物进行PCR。
优选地，所述第二引物包含：SEQ.IDNO.18，并且所述多核苷酸包含SEQ.IDNOS.3-16的3’末端6个核苷酸中的至少4或5个核苷酸；或所述第二引物包含SEQ.IDNO.35，并且所述多核苷酸含有SEQ.IDNOS.20-33的3’末端6个核苷酸中的至少4或5个核苷酸。
另外，该方法还包含以下步骤：用对照引物对所述样品进行PCR，并比较PIK3CA基因的扩增和用所述多核苷酸和第二引物的扩增。
优选地，所述对照引物含有SEQIDNO.37和39。
通常，所述多核苷酸含有淬灭基团和荧光团，并且其中步骤b)包括使所述混合物暴露于在不存在淬灭基团时荧光团对其响应的波长的光下，并检测在不存在淬灭基团的情况下荧光团发射波长处的光。
优选PIK3CA基因是GenBank登录号NM_006218版本号NM_006218.2GI:54792081可获得的序列,该序列通过参考整合在本发明中。
当说明书中提到一个参照序列“3’末端6个核苷酸中至少4或5个”时，指所述参照序列的所述6个核苷酸中的任意一个或两个核苷酸可能缺失或被不同的核苷酸取代。当然，在一些实施方式中，该序列含有参照序列的全部6个核苷酸。
在本说明书中，“ARMS”是例如EP-A-0332435中所公开的的扩增阻滞突变***。
当在本说明书中提到一种多核苷酸相对于参照多核苷酸的百分比时，这可以通过本领域已知的算法确定。
例如，两条序列之间的相同性百分数可以采用默认参数用BLASTP算法2.2.2版(Altschul,StephenF.,ThomasL.Madden,AlejandroA.JinghuiZhang,ZhengZhang,WebbMiller,和DavidJ.Lipman(1997),“缺口BLAST和PSI-BLAST：新一代蛋白质数据库检索程序”,核酸研究.25:3389-3402)加以确定。
附图说明
图1显示了对含有突变PIK3CA基因的样品进行Scorpions检测和测序的结果。
发明详述
本发明的实施方式提供了可用于在含有核酸的样品中检测PIK3CA基因突变的检测法的多核苷酸引物。
在具体实施方式中，所述多核苷酸引物是正向和反向引物，它们与PIK3CA基因杂交，从而发生PCR扩增。因此，所述正向引物与所述反向引物相反链的上游杂交，并且正向和反向引物共同确定了在PCR中扩增出的扩增子序列。选择正向引物序列，使其不和野生型序列互补，但能与突变PIK3CA序列杂交。
为了检测样品中突变PIK3CA基因的存在，将引物与样品混合。然后在样品中加入PCR必需的试剂(合适的核苷酸三磷酸、DNA聚合酶和缓冲液)，进行PCR。如果样品含有正向引物能与之杂交的突变序列，那么在PCR过程中扩增出扩增子，从而表明样品中突变序列的存在。如果样品不含突变序列，那么正向引物与PIK3CA序列结合的效率低，因此几乎没有，或不存在扩增子序列的扩增。
为了检测突变E542K，所述正向引物序列可以是SEQIDNO.3-9之一，优选为SEQIDNO.5。为了检测突变E545K，所述正向引物序列可以是SEQIDNO.10-16之一，优选为SEQIDNO.14。为了检测突变H1047R，所述正向引物序列可以是SEQIDNO.20-26之一，优选为SEQIDNO.21。为了检测突变H1047L，所述正向引物序列可以是SEQIDNO.27-33之一，优选为SEQIDNO.28。然而，应理解正向引物的精确序列不需要与这些序列相同，只要正向引物与突变序列比与野生序列的杂交更容易。在上述序列中，引物的最后6个核苷酸(即3'末端的核苷酸)提供了结合特异性，因此这些核苷酸必需与给定序列相同。
为了检测样品中形成的扩增子的存在，反向引物在本发明实施方式中被称作“Scorpions”引物。Scorpions引物在WO-A-99/066071中被详细描述，在此通过参考整合在本发明中。Scorpions引物含有与一个基因(在本发明中为PIK3CA)的第一靶序列互补的引物序列和一个尾序列，其包含与两个互补序列侧接的探针序列。在引物序列和尾序列之间提供了DNA聚合酶封闭部分(例如六甘醇(HEG)单体)。在尾序列的一端提供了荧光团，在尾序列的另一端提供了淬灭基团。使用时，Scorpions引物的引物序列在正常方式的PCR中作为反向引物，并且因此整个Scorpions引物(包括尾序列)被掺入各扩增子。DNA聚合酶封闭部分防止尾序列复制。因此，尾序列中互相互补的序列倾向互相杂交，使荧光团和淬灭基团靠近并防止荧光团发光。然而，如果扩增子含有与所述探针序列互补的第二靶序列，所述探针序列优先与第二靶序列结合，使互补序列分开。这导致荧光团和淬灭基团在空间上分开，从而使荧光团响应不同波长的入射光而发出一定波长的光。因此，Scorpions引物能够轻易检测扩增子，并且避免假阳性结果(例如由引物二聚体引起的)，因为只有扩增子含有第二靶序列时才会产生信号。
所述荧光团可以是Hex(4,7,2',4',5',7'-六氯-(3',6'-二特戊酰基荧光素基)-6-羧酰胺基己基]-1-O-(2-氰基乙基)-(N,N-二异丙基)-亚磷酰胺),Fam([(3',6'-二特戊酰基荧光素基)-6-羧酰氨基己基]-1-O-(2-氰基乙基)-(N,N-二异丙基)-亚磷酰胺)或Rox(5,6,-羧基-X-罗丹明)。所述淬灭基团可以是Dabcyl(5’-二甲氧基三苯甲氧-5-[(N-4'-羧基-4-(二甲基氨基)-偶氮苯)-氨基己基-3-丙烯亚酰胺]-2'-脱氧尿苷-3'-[(2-氰基乙基)-(N,N-二异丙基)]-亚磷酰胺)。
在本发明的实施方式中，提供了用于检测E542K和E545K突变的Scorpions引物，其中引物序列是SEQIDNO.18，探针序列是SEQIDNO.17。提供了用于检测H1047R和H1047L突变的Scorpions引物，其中引物序列是SEQIDNO.35，探针序列是SEQIDNO.34。
然而应理解，使用Scorpions引物不是本发明必需的，也可使用其它检测扩增子合成的方法，例如TaqManTM产物检测，如专利号US-A-5487972和US-A-5210015中所述。
在一些实施方式中，还进行对照试验，以检测PIK3CA基因在样品中的总浓度。这是通过用确定PIK3CA基因中另一个区域内的扩增子的对照正向和反向引物进行单独PCR反应实现的。优选正向引物是SEQIDNO.37，反向引物是Scorpions引物，其中引物序列是SEQIDNO.39，探针序列是SEQIDNO.38。然后将产生阈值数量的对照扩增子所需的PCR循环数与产生含有突变序列的扩增子阈值数的PCR循环数比较，以评估样品中PIK3CA基因的突变拷贝的比例。该对照试验通常与所述检测法分开进行。
所述PCR检测优选以多重实时PCR检测的方式进行。
核酸测试样品通常是血液、粪便、痰、结肠洗出液、支气管洗出液或其它体液样品，或从个体获得的组织。所述个体通常是人，优选智人(Homosapiens)。应理解，测试样品同样可以是对应于所述测试样品中的序列的一个核酸序列。即，首先可以用任何常规技术，例如热循环核酸扩增，尤其是PCR，或全基因组扩增(WGA)扩增样品核酸中的全部或部分区域，然后用于本发明的方法。
可使用任何常用的用于聚合的酶，只要它不在任何显著的程度上影响DNA聚合酶区分正常和突变模板序列的能力。常用的酶的例子包括没有显著3’-5'外切核酸酶活性的热稳定酶，例如TaqDNA聚合酶，尤其是“AmpliTaqGold”TMDNA聚合酶(PEAppliedBiosystems),Stoffel片段，或其它合适的Taq或Tth(嗜热栖热菌Thermusthermophilus)DNA聚合酶的N-末端缺失修饰形式。
在本发明的其它实施方式中，提供了试剂盒，其含有本发明的一种或多种多核苷酸和进行PCR反应所需的核苷酸三磷酸、DNA聚合酶和缓冲液。优选试剂盒含有用于检测特定突变的正向和反向引物，以及正向和反向对照引物。
实施例
材料和方法
根据PIK3CA基因(登录号:NM_006218)中4种最常见的突变设计引物。设计ARMS引物以检测外显子20中的两个突变:H1047R和H1047L;以及外显子9中的两个突变:E452K和E454K。对PIK3CA基因中的cDNA2450位设计对照引物。
还设计了Scorpions。为了实现在每个反应中进行多重试验，用不同荧光团标记三个Scorpion引物。
引物设计
针对每个靶区域设计多个特异性的ARMS引物。E542K和E545K突变的靶区域分别如下如SEQIDNO.1和2所示(突变碱基在括弧中显示，其中正常形式在前)。针对所述突变的正向引物也如下所示(SEQIDNO.3-16)。为了增强对这些反应的特异性，在接近3'-末端使用了额外的引物错配(在引物序列中用下划线表示)。针对所述实验使用了优化引物(E542K-2和E545K-4)。可与所述引物序列使用的Scorpions引物如SEQIDNO.17和18所示。Scorpions引物和靶区域之间的对应区域用一致的高亮或下划线标出。
外显子9区域
AACAGAGAATCTCCATTTTAGCACTTACCTGTGACTCCATAGAAAATCTTTCTCCTGCTCAGTGAT AGAGAGAGGATTGTTCTTTGTCATTTTCCCTTAATTCATTGTCTCTAGCTAGTCTGTTACTCTGTAAAATAAAATAATATCTTATATA(SEQIDNO.1)
AACAGAGAATCTCCATTTTAGCACTTACCTGTGACTCCATAGAAAATCTTTCTCCTG AGTGATTTCAGAGAGAGGATTGTTCTTTGTCATTTTCCCTTAATTCATTGTCTCTAGCTAGTCTGTTACTCTGTAAAATAAAATAATATCTTATATA(SEQIDNO.2)
外显子20区域
H1047R和H1047L突变的靶区域如下如SEQIDNO:19所示(突变碱基如括弧中所示，其中正常形式在前)。针对突变的正向引物也如下所示(SEQIDNO.20-33)。为了增强对这些反应的特异性，在接近3'-末端使用了额外的引物错配(如引物序列中下划线的所示)。针对所述实验使用了优化引物(H1047R-1和H1047L-1)。可与所述引物序列使用的Scorpions引物如SEQIDNO.34和35所示。Scorpions引物和靶区域之间的对应区域用一致的高亮或下划线标出。
AGTGCAGTGTGGAATCCAGAGTGAGCTTTCATTTTCTCAGTTATCTTTTCAGTTCAATGCATGCTGTTTAATTGTGTGGAAGATCCAATCCATTTTTGTTGTCCAGCCACCAT GTGCATCATTCATTTGTTTTCTTGCTCAGTTTTATCTAAGGCTAGGGTCTTTCGAATGTATGCAATGTCATCAAAAGATTGTAGTTCTGGCATTCCAGAGCCAAGCATCATTGAGAAAAGATTTATGAAGAGATTGGCATGCTGTCGAATAGCTAGATAAGCCTT(SEQIDNO.19)
对照引物
对照引物如下所示。Scorpions引物和靶区域之间的对应区域用一致的高亮或下划线标出。
AGGCTTGAAGAGTGTCGAATTATGTCCTCTGCAAAAA TGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAACAATGAGATCATCTTTAAAAATGGGGATGG(SEQIDNO.36)
所有引物由Invitrogen合成和提供。PCR缓冲液、Taq和镁由Eurogentec提供，dNTP购自AbgeneLtd。Scorpions由ATDBio合成和提供。
试验在包含一个对照检测和2个ARMS检测(1x外显子9和1x外显子20)的2个反应中多重进行。在含有1xPCR缓冲液、4.0mMMgCl2、200μMdNTP混合物、0.25μM的各引物(对照引物和2个ARMS引物)以及0.25μM的各Scorpion(对照Scorpion(SEQIDNO.38和39)、外显子20Scorpion(SEQIDNO.34和35)、以及外显子9Scorpion(SEQIDNO.17和18))的25微升反应体系中进行试验。在各反应中加入2.5微升DNA模板。每次反应用2.5单位Taq聚合酶多重使用(multiplex)H1047R和E542K引物。每次反应用3.0单位Taq聚合酶多重使用H1047L和E545K引物。所用的E542K引物是E542K-2(SEQIDNO.5)。所用的E545K引物是E545K-4(SEQIDNO.14)。所用的H1047R引物是H1047R-1(SEQIDNO.21)。所用的H1047L引物是H1047L-1(SEQIDNO.28)。
在所有的情况下，反应在下列条件下在StratageneMx3000P上扩增：95℃10分钟，然后是45轮的90℃30秒和60℃1分钟循环。
根据Higuchi等[2]所述的方法构建携带点突变的DNA盒作为阳性对照。简单说，使用相应的外部和变构(mutamer)引物产生具有互补端的半个盒，每个半盒含有一个突变碱基。混合这些PCR产物，并用内部嵌套(nested)引物扩增。互补的半盒的自发引导和随后的扩增产生了具有突变碱基的终产物。对产物测序，以确定已建立了正确的序列。对每个感兴趣的突变重复该过程。将DNA盒与等量的基因组DNA混合，以产生100%阳性对照。
实施例1
为了确定反应和引物的特异性，每个反应使用5-50ng基因组DNA进行各试验，以评估错配引物延伸导致的临界信号。对于每个反应，测定ΔCt值(对照Ct-突变Ct)(Ct=阈值循环)。对每个DNA浓度进行6次反应，并对各种情况重复三次，以确定截留ΔCt值，在该值以下，任何扩增可被认为是由于存在突变序列而不是由于临界信号。截留ΔCt值被确定为比每个试验的所有反应中的最小ΔCt值小1Ct。对于H1047R和H1047L试验，截留ΔCt被定为12，对于E542K试验，截留ΔCt是9，对于E545K试验，截留ΔCt是8。
实施例2
为了评估试验的灵敏度，将5个突变DNA拷贝稀释于不同浓度的基因组DNA中，使得最终浓度为突变DNA相对于野生型DNA的5,2,1,0.5和0.1%。表1显示了4个ARMS试验的灵敏度。该表格显示了在野生型DNA背景下递减浓度的突变DNA的ΔCt值。预定的截留ΔCt如最后一栏所示。外显子20试验能够在仅占0.1%总DNA的情况下检测5个突变DNA拷贝(在先前预定的截留ΔCt下)。外显子9试验能够在仅占1%总DNA的情况下检测5个突变DNA拷贝，其中△Ct位于先前预定的截留值范围内)(表1)。
表1：
实施例3
用含有突变H1047R(HCT-116)和E545K(MCF-7)的细胞系的混合物比较ARMS试验与测序相比的相对灵敏度。两个细胞系对于突变都是杂合的。用Samuels等[1]所述的引物和PCR循环条件进行测序。ARMS试验和测序在突变基因占总混合物100%,50%,30%,10%和1%的浓度下进行。结果如图1所示，其中“Scorpions”标题下所示的结果显示了在持续的PCR循环后扩增子拷贝数的增加(使用对照引物和突变引物的结果用单独的线条表示)。在标题“DNA测序”下所示的是对混合物中基因反向链测序的结果。当H1047R突变体少于50%的总混合物时，测序不能检测其存在，而当存在的E545K突变体少于30%的总混合物时，也不能检测其存在。相反，使用本发明引物的试验能检测以1%浓度存在的突变体。
实施例4
对从通过ARMS/Scorpion检测对存在PIK3CA突变进行了评估的不同肿瘤类型的新鲜冷冻组织中提取的DNA进行该试验。总共从279个肿瘤样品中获得了DNA。该试验在49个结肠癌样品中的5个(10.2%)，49个乳腺癌样品中的19个(38.7%)，51个肺癌样品中的1个(1.9%)，和34个黑素瘤样品中的1个(2.9%)中报告了突变。在50个***或46个卵巢癌样品中未检测到突变。在对于PIK3CA突变阳性的结肠样品中，3个是H1047R,1个是H1047L，而1个是E542K；在对于PIK3CA阳性的乳腺癌样品中，15个是H1047R,1个是H1047L，而3个是E545K；对于PIK3CA突变阳性的肺癌样品和黑素瘤样品中的两个突变都是H1047R。测序仅仅鉴定出被检测出的26个突变中的14个(53%)。测序检测出一乳腺癌标本中的突变，它是ARMS试验并没有设计用于检测的(c1634A>G;pE545G)。这不是新的突变，且先前已经在乳腺癌和结肠癌中进行过描述[3-5]。
除了卵巢癌，所分析的样品中PIK3CA突变的出现率与先前研究一致[1,3-9]。在卵巢癌中先前已经描述过PIK3CA突变，但被认为可能与子宫内膜样和透明细胞癌有关[8,10]。所有在本研究中测试的卵巢癌都是严重腺癌，这可能解释了为何不存在任何PIK3CA突变。
ARMS试验明显在临床样品中鉴定了比直接测序所见更多的突变。细胞系混合物确定该试验比测序在检测感兴趣的PI3KCA突变中更灵敏。可能同时含有肿瘤和正常组织的临床样品的异源性意味着在一些情况下，突变发生率将会比测序法可检测的低，因此ARMS试验更适合临床应用。缺点是，仅有某些ARMS特异突变可被检测。然而在该系列的279个样品中，在PI3KCA基因的外显子9或20中仅检测出一个ARMS试验没有设计检测的突变。
总的说，实施例显示了本发明提供了一种用于检测PI3KCA基因中4个最常见突变的灵敏的高通量的检测法。该检测法可用于少量DNA，并可检测样品中低水平的突变PIK3CA。
Claims (5)
1.核苷酸序列如SEQIDNO.21所示正向引物用于制备PCR法检测PIK3CA基因中突变的试剂盒的用途，所述试剂盒还包含反向引物，所述反向引物在PIK3CA序列片段内的对应区域位于正向引物互补区的下游。
2.如权利要求1所述的用途，所述反向引物的序列如SEQIDNO.35所示。
3.一种多核苷酸分子，由SEQIDNO.21所示核苷酸序列构成。
4.一种试剂盒，含有至少两条引物，其中，第一引物是正向引物，第二引物是反向引物，所述第一引物的核苷酸序列如SEQIDNO.21所示，所述第二引物在PIK3CA序列片段内的对应区域位于第一引物互补区的下游。
5.如权利要求4所述的试剂盒，所述第二引物的序列如SEQIDNO.35所示。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0719034.1 | 2007-09-28 | ||
| GB0719034A GB2453173A (en) | 2007-09-28 | 2007-09-28 | Polynucleotide primers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880110038.7A Division CN102119222B (zh) | 2007-09-28 | 2008-09-29 | 多核苷酸引物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103952466A CN103952466A (zh) | 2014-07-30 |
| CN103952466B true CN103952466B (zh) | 2016-07-06 |
Family
ID=38701889
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310752306.8A Expired - Fee Related CN103834724B (zh) | 2007-09-28 | 2008-09-29 | 多核苷酸引物 |
| CN201310752451.6A Expired - Fee Related CN103695558B (zh) | 2007-09-28 | 2008-09-29 | 多核苷酸引物 |
| CN201310752245.5A Expired - Fee Related CN103952466B (zh) | 2007-09-28 | 2008-09-29 | 多核苷酸引物 |
| CN200880110038.7A Expired - Fee Related CN102119222B (zh) | 2007-09-28 | 2008-09-29 | 多核苷酸引物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310752306.8A Expired - Fee Related CN103834724B (zh) | 2007-09-28 | 2008-09-29 | 多核苷酸引物 |
| CN201310752451.6A Expired - Fee Related CN103695558B (zh) | 2007-09-28 | 2008-09-29 | 多核苷酸引物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880110038.7A Expired - Fee Related CN102119222B (zh) | 2007-09-28 | 2008-09-29 | 多核苷酸引物 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US8901285B2 (zh) |
| EP (7) | EP2505671B1 (zh) |
| JP (1) | JP5719593B2 (zh) |
| KR (4) | KR101548758B1 (zh) |
| CN (4) | CN103834724B (zh) |
| AU (1) | AU2008303400B2 (zh) |
| BR (1) | BRPI0817444A2 (zh) |
| CA (2) | CA3010064A1 (zh) |
| ES (6) | ES2531994T3 (zh) |
| GB (1) | GB2453173A (zh) |
| MX (1) | MX2010003486A (zh) |
| RU (1) | RU2491289C2 (zh) |
| WO (1) | WO2009040557A2 (zh) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2453173A (en) | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| EP3246332B1 (en) * | 2010-01-12 | 2019-07-10 | Siemens Healthcare Diagnostics Inc. | Oligonucleotides and methods for detecting pik3ca mutations |
| JP2013081450A (ja) * | 2011-09-27 | 2013-05-09 | Arkray Inc | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット |
| CN102453765B (zh) * | 2011-11-03 | 2013-07-24 | 厦门艾德生物医药科技有限公司 | Pik3ca基因驱动突变的检测探针、引物及试剂盒 |
| SG10201608001RA (en) | 2012-03-29 | 2016-11-29 | Novartis Ag | Pharmaceutical diagnostic |
| CN102816839A (zh) * | 2012-07-06 | 2012-12-12 | 杭州艾迪康医学检验中心有限公司 | 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒 |
| EP2711432A1 (en) * | 2012-09-21 | 2014-03-26 | Genomica S.A.U. | Method for detection of BRAF and PI3K mutations |
| CA2899712C (en) * | 2013-03-13 | 2021-01-05 | F. Hoffmann-La Roche Ag | Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene |
| CN103773837A (zh) * | 2013-06-25 | 2014-05-07 | 宁波有成生物医药科技有限公司 | 一种pik3ca基因突变荧光定量pcr检测试剂盒及检测方法 |
| RU2549682C1 (ru) * | 2013-10-21 | 2015-04-27 | Общество с ограниченной ответственностью "БИОЧИП-ИМБ" | Способ анализа соматических мутаций в гене pi3k с использованием lna-блокирующей мультиплексной пцр и последующей гибридизацией с олигонуклеотидным биологическим микрочипом (биочипом) |
| WO2015161274A1 (en) * | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Pik3ca fusions |
| CN105274188A (zh) * | 2014-05-29 | 2016-01-27 | 北京雅康博生物科技有限公司 | Pik3ca基因突变检测试剂盒 |
| CN106715723B (zh) * | 2014-08-07 | 2021-03-30 | 法马西斯特有限责任公司 | 测定样品中pik3ca突变状态的方法 |
| US10276072B2 (en) * | 2014-09-03 | 2019-04-30 | Washme Properties, Llc | Illuminated sign |
| CN105441533B (zh) * | 2014-11-29 | 2019-07-05 | 上海赛安生物医药科技有限公司 | Pik3ca基因突变检测体系及其试剂盒 |
| CN104531875A (zh) * | 2014-12-30 | 2015-04-22 | 宁波有成生物医药科技有限公司 | 一种MyD88基因突变荧光定量PCR检测试剂盒及检测方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006091899A2 (en) * | 2005-02-24 | 2006-08-31 | Amgen Inc. | Epidermal growth factor receptor mutations |
| WO2006106316A2 (en) * | 2005-04-04 | 2006-10-12 | Dxs Limited | Polynucleotide primers |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| US20030225013A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of phosphoinositide-3-kinase, regulatory subunit 4, p150 expression |
| US5847972A (en) | 1993-09-24 | 1998-12-08 | Eick; Stephen Gregory | Method and apparatus for graphically analzying a log-file |
| US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
| US5948664A (en) | 1996-02-29 | 1999-09-07 | The Regents Of The University Of California | PI 3-kinase polypeptides |
| US6133419A (en) * | 1996-11-01 | 2000-10-17 | Onyx Pharmaceuticals, Inc. | Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof |
| US6277563B1 (en) | 1997-01-16 | 2001-08-21 | The Regents Of The University Of California | Genetic alterations associated with cancer |
| US5955277A (en) | 1997-05-05 | 1999-09-21 | Novo Nordisk A/S | Mutant cDNA encoding the p85α subunit of phosphatidylinositol 3-kinase |
| US5994076A (en) * | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
| US7122373B1 (en) | 1998-05-14 | 2006-10-17 | Nuvelo, Inc. | Human genes and gene expression products V |
| US8101349B2 (en) | 1997-12-23 | 2012-01-24 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells and their methods of use II |
| US6537751B1 (en) | 1998-04-21 | 2003-03-25 | Genset S.A. | Biallelic markers for use in constructing a high density disequilibrium map of the human genome |
| GB9812768D0 (en) * | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
| US6274237B1 (en) * | 1999-05-21 | 2001-08-14 | Chisso Corporation | Potentially crimpable composite fiber and a non-woven fabric using the same |
| JP2003530309A (ja) * | 1999-10-26 | 2003-10-14 | イミューソル インコーポレイテッド | 増殖性皮膚疾患又は増殖性眼疾患を治療するリボザイム療法 |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| WO2002027028A1 (en) | 2000-09-28 | 2002-04-04 | Atairgin Technologies, Inc. | A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes |
| USH2191H1 (en) * | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| CN1358850A (zh) * | 2000-12-13 | 2002-07-17 | 上海博德基因开发有限公司 | 一种新的多肽——人磷脂酰肌醇3(PtdIns 3)－激酶17.6和编码这种多肽的多核苷酸 |
| CA2372542A1 (en) | 2001-02-20 | 2002-08-20 | Pfizer Products Inc. | Transgenic animals containing a dominant negative mutant form of the p85 subunit of pi-3 kinase |
| US20030162174A1 (en) * | 2001-06-11 | 2003-08-28 | Sutherland John W. | Detecting nucleic acid deletion sequences |
| WO2003025175A2 (fr) | 2001-09-17 | 2003-03-27 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
| US20030182669A1 (en) | 2002-03-19 | 2003-09-25 | Rockman Howard A. | Phosphoinositide 3-kinase mediated inhibition of GPCRs |
| US7955800B2 (en) | 2002-06-25 | 2011-06-07 | Advpharma Inc. | Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients |
| DE60332948D1 (de) * | 2002-07-19 | 2010-07-22 | Althea Technologies Inc | Strategien zur genexpressionsanalyse |
| US7217807B2 (en) * | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| US20070054278A1 (en) | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
| CA2560696C (en) | 2004-03-02 | 2019-06-25 | The Johns Hopkins University | Mutations of the pik3ca gene in human cancers |
| EP1753875A2 (en) * | 2004-05-07 | 2007-02-21 | Applera Corporation | Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof |
| WO2005116265A2 (en) * | 2004-05-26 | 2005-12-08 | Wyeth | Probe arrays for expression profiling of rat genes |
| WO2006094149A2 (en) | 2005-03-01 | 2006-09-08 | Exact Sciences Corporation | Methods and compositions for detecting adenoma |
| EP1861958B1 (en) * | 2005-03-14 | 2011-01-26 | Koninklijke Philips Electronics N.V. | MEASURING AND MONITORING QoS IN SERVICE DIFFERENTIATED WIRELESS NETWORKS |
| EP1948816B1 (en) * | 2005-10-24 | 2011-12-07 | The Johns Hopkins University | Improved methods for beaming |
| JP4477575B2 (ja) * | 2005-12-14 | 2010-06-09 | 株式会社日立製作所 | 大腸がんの検査に使用する遺伝子セット |
| WO2007106407A2 (en) * | 2006-03-10 | 2007-09-20 | Wyeth | Microarray for monitoring gene expression in multiple strains of streptococcus pneumoniae |
| GB2453173A (en) | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| AU2008333714A1 (en) | 2007-12-03 | 2009-06-11 | Enzon Pharmaceuticals, Inc. | RNA antagonist compounds for the modulation of PIK3CA expression |
-
2007
- 2007-09-28 GB GB0719034A patent/GB2453173A/en not_active Withdrawn
-
2008
- 2008-09-29 CN CN201310752306.8A patent/CN103834724B/zh not_active Expired - Fee Related
- 2008-09-29 ES ES10158523.0T patent/ES2531994T3/es active Active
- 2008-09-29 MX MX2010003486A patent/MX2010003486A/es active IP Right Grant
- 2008-09-29 WO PCT/GB2008/003306 patent/WO2009040557A2/en active Application Filing
- 2008-09-29 EP EP12169586.0A patent/EP2505671B1/en not_active Not-in-force
- 2008-09-29 ES ES12169604T patent/ES2531055T3/es active Active
- 2008-09-29 EP EP12169604.1A patent/EP2508624B1/en not_active Not-in-force
- 2008-09-29 AU AU2008303400A patent/AU2008303400B2/en not_active Ceased
- 2008-09-29 CA CA3010064A patent/CA3010064A1/en not_active Abandoned
- 2008-09-29 CN CN201310752451.6A patent/CN103695558B/zh not_active Expired - Fee Related
- 2008-09-29 EP EP12169594.4A patent/EP2505672B1/en not_active Not-in-force
- 2008-09-29 EP EP10158519.8A patent/EP2236627B1/en not_active Not-in-force
- 2008-09-29 KR KR1020107009180A patent/KR101548758B1/ko active IP Right Grant
- 2008-09-29 RU RU2010116772/10A patent/RU2491289C2/ru not_active IP Right Cessation
- 2008-09-29 KR KR1020157006583A patent/KR101543215B1/ko active IP Right Grant
- 2008-09-29 EP EP12169599.3A patent/EP2505673B1/en not_active Not-in-force
- 2008-09-29 EP EP08806456A patent/EP2205760B1/en not_active Not-in-force
- 2008-09-29 KR KR1020157006582A patent/KR101543214B1/ko active IP Right Grant
- 2008-09-29 ES ES10158519.8T patent/ES2532141T3/es active Active
- 2008-09-29 BR BRPI0817444-0A patent/BRPI0817444A2/pt active Search and Examination
- 2008-09-29 CN CN201310752245.5A patent/CN103952466B/zh not_active Expired - Fee Related
- 2008-09-29 KR KR1020157006584A patent/KR101543216B1/ko active IP Right Grant
- 2008-09-29 ES ES12169599.3T patent/ES2620289T3/es active Active
- 2008-09-29 ES ES12169586.0T patent/ES2622885T3/es active Active
- 2008-09-29 JP JP2010526365A patent/JP5719593B2/ja active Active
- 2008-09-29 CA CA2700710A patent/CA2700710C/en not_active Expired - Fee Related
- 2008-09-29 ES ES12169594.4T patent/ES2532225T3/es active Active
- 2008-09-29 US US12/680,621 patent/US8901285B2/en not_active Expired - Fee Related
- 2008-09-29 EP EP10158523.0A patent/EP2239341B1/en not_active Not-in-force
- 2008-09-29 CN CN200880110038.7A patent/CN102119222B/zh not_active Expired - Fee Related
-
2013
- 2013-10-24 US US14/062,163 patent/US9863003B2/en not_active Expired - Fee Related
-
2015
- 2015-09-18 US US14/858,188 patent/US10196692B2/en not_active Expired - Fee Related
- 2015-09-18 US US14/858,196 patent/US10190171B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006091899A2 (en) * | 2005-02-24 | 2006-08-31 | Amgen Inc. | Epidermal growth factor receptor mutations |
| WO2006106316A2 (en) * | 2005-04-04 | 2006-10-12 | Dxs Limited | Polynucleotide primers |
Non-Patent Citations (1)
| Title |
|---|
| PIK3CA基因突变与癌症的关系;王红洁等;《医学分子生物学杂志》;20061231;第3卷(第5期);第348页第2段 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103952466B (zh) | 多核苷酸引物 | |
| CN103589795A (zh) | 一种检测与肺癌易感性及化疗敏感性相关基因的多态性的试剂盒及其应用 | |
| CN111440865A (zh) | Fat3基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用 | |
| Kit et al. | The Detection of Double Mutations in KRAS Depends on the Mutation-Detection Assay Used To the Editor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160706 Termination date: 20190929 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |